Indivior Share Price Rose 4.52% on the Actavis Patent Settlement

The Indivior PLC (LON: INDV) share price rose 4.52% after announcing that it had agreed with Actavis Laboratories UT, Inc. regarding the patent dispute between the two companies. The agreement was initiated to address and resolve ongoing patent disputes linked to Actavis's attempt to introduce a generic version of a critical medication used in addiction treatment.

The announcement revealed that Indivior Inc. and Indivior UK Limited, both integral parts of the Indivior group, have reached a settlement agreement with Actavis Laboratories UT, Inc. (“Actavis”), which operates under the umbrella of the globally recognised Teva Pharmaceuticals.

The crux of the dispute involved Actavis's Abbreviated New Drug Application (ANDA) for a generic variant of buprenorphine and naloxone sublingual film. These substances are pivotal in the treatment of opioid addiction, providing a combined therapeutic approach that has been proven effective in various clinical settings.

The settlement is a significant turn of events, as Indivior has consented to grant Actavis a license associated with U.S. Patent No. 11,135,216. This license is a critical element of the agreement, enabling Actavis to introduce its generic film products in the United States market.

However, this launch is scheduled not to occur before January 31, 2025, with a caveat that this timeline could be adjusted if the patent claims are rendered invalid or unenforceable in a definitive judicial ruling.

The agreement between Indivior and Actavis represents more than just a resolution to a legal dispute. It embodies Indivior's ongoing commitment to combat addiction and mental health issues on a worldwide scale. 

Indivior, as a front-runner in the pharmaceutical industry, continues to dedicate its efforts to advancing treatments and solutions for addiction. Their mission and vision extend to ensuring that patients globally have access to evidence-based treatment for chronic conditions, with a particular focus on substance use disorder (SUD) and its related complexities.

This settlement underscores Indivior's holistic approach to addressing the challenges of SUD. The company strives to redefine SUD, shifting the global perspective from viewing it as a human crisis to recognising and treating it as a chronic disease. 

This goal is reflected in Indivior's extensive and diverse portfolio of treatments specifically targeting opioid use disorder (OUD). Moreover, Indivior is actively engaged in the development of new product candidates. 

Indivior share price. 

The Indivior share price rose 4.52% to trade at 1197.25p from Tuesday’s closing price of 1145.50p.